EP1239866A4 - INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS - Google Patents

INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS

Info

Publication number
EP1239866A4
EP1239866A4 EP00984214A EP00984214A EP1239866A4 EP 1239866 A4 EP1239866 A4 EP 1239866A4 EP 00984214 A EP00984214 A EP 00984214A EP 00984214 A EP00984214 A EP 00984214A EP 1239866 A4 EP1239866 A4 EP 1239866A4
Authority
EP
European Patent Office
Prior art keywords
neu
her2
peptide
nucleic acid
immune responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00984214A
Other languages
German (de)
French (fr)
Other versions
EP1239866A1 (en
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Robert Chesnut
Esteban Celis
Elissa Keogh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US45829999A priority Critical
Priority to US458299 priority
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to PCT/US2000/033591 priority patent/WO2001041787A1/en
Publication of EP1239866A1 publication Critical patent/EP1239866A1/en
Publication of EP1239866A4 publication Critical patent/EP1239866A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/605MHC molecules or ligands thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
EP00984214A 1999-12-10 2000-12-11 INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS Withdrawn EP1239866A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US45829999A true 1999-12-10 1999-12-10
US458299 1999-12-10
PCT/US2000/033591 WO2001041787A1 (en) 1999-12-10 2000-12-11 INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05008363A EP1568373A3 (en) 1999-12-10 2000-12-11 Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05008363A Division EP1568373A3 (en) 1999-12-10 2000-12-11 Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions

Publications (2)

Publication Number Publication Date
EP1239866A1 EP1239866A1 (en) 2002-09-18
EP1239866A4 true EP1239866A4 (en) 2005-02-09

Family

ID=23820228

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00984214A Withdrawn EP1239866A4 (en) 1999-12-10 2000-12-11 INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
EP05008363A Withdrawn EP1568373A3 (en) 1999-12-10 2000-12-11 Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05008363A Withdrawn EP1568373A3 (en) 1999-12-10 2000-12-11 Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions

Country Status (5)

Country Link
EP (2) EP1239866A4 (en)
JP (1) JP2003530083A (en)
AU (1) AU2087401A (en)
CA (1) CA2393738A1 (en)
WO (1) WO2001041787A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771998B2 (en) 2001-11-29 2010-08-10 Dandrit Biotech A/S Pharmaceutical composition for inducing an immune response in a human or animal
FR2837837B1 (en) * 2002-03-28 2006-09-29 Roussy Inst Gustave common peptide epitopes of antigens of the same multigene family
AU2003292127A1 (en) * 2002-11-26 2004-06-18 Antarus Lifescience Gmbh Method for the generation of antibodies against a desired antigen using preselected animals for immunization
EP1903056A3 (en) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
US7597894B2 (en) * 2003-03-05 2009-10-06 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
EP1620456B1 (en) 2003-04-18 2014-02-26 Biotech Synergy, Inc. Hla-a2 tumor associated antigen peptides and compositions
JPWO2005007694A1 (en) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド HER2 / neu peptide and its therapeutic applications
EP1682159A4 (en) 2003-10-16 2010-07-21 Stephen John Ralph Immunomodulating compositions and uses therefor
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP2007511534A (en) * 2003-11-13 2007-05-10 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ Compositions and methods for synergistic induction of antitumor immunity
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
BRPI0516284A (en) 2004-09-23 2008-09-02 Genentech Inc Built antibody with cysteine, a method to select antibodies, conjugates of antibody-drug, pharmaceutical composition, method of killing or inhibiting tumor cell proliferation, methods of inhibiting cell proliferation and tumor cell growth, article of manufacture and method to produce a compound
JP4961706B2 (en) * 2004-09-29 2012-06-27 東レ株式会社 Hla Class ii restricted novel cancer antigen peptides
CA2634480C (en) 2005-12-23 2013-10-15 Vaxon Biotech Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof
US7972602B2 (en) * 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
JP2011502484A (en) * 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Hla-dr binding peptides and their uses
JP2010006705A (en) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Her2 subset
JP5792630B2 (en) 2009-01-28 2015-10-14 エピミューン,インコーポレイティド Pan-dr binding polypeptides and uses thereof
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2011239507B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
US9765380B2 (en) * 2010-12-08 2017-09-19 Expression Pathology, Inc. Truncated HER2 SRM/MRM assay
EP2655401B1 (en) * 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
US9821043B2 (en) * 2011-09-15 2017-11-21 Medigene Ag Anti-HER2 vaccine based upon AAV derived multimeric structures
EP2814836B1 (en) * 2012-02-17 2017-11-08 Mayo Foundation For Medical Education And Research Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and their complexes
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
KR20150085814A (en) 2012-10-12 2015-07-24 에이디씨 테라퓨틱스 에스에이알엘 Pyrrolobenzodiazepine-antibody conjugates
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
JP6307519B2 (en) 2012-12-21 2018-04-04 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and its conjugate
JP2016505586A (en) 2012-12-21 2016-02-25 スパイロジェン・エス・アー・エール・エルSpirogen Sarl Asymmetric pyrrolobenzodiazepine dimer for use in the treatment of proliferative diseases and autoimmune diseases
CA2840974A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
CA2840937A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
BR112015021965A2 (en) 2013-03-13 2017-07-18 Medimmune Ltd pyrrolobenzodiazepines and conjugates thereof
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20150131203A (en) 2013-03-13 2015-11-24 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN105636612A (en) 2013-08-12 2016-06-01 基因泰克公司 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
MX2016007825A (en) 2013-12-16 2016-09-07 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc antibody and conjugated drug, compound, method of treatment and pharmaceutical composition
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
BR112017005393A2 (en) 2014-09-17 2017-12-05 Genentech Inc compound of formula I, the method of preparation of a conjugate of formula, formula A1 conjugate, composition comprising a mixture of antibody-drug conjugate compounds, pharmaceutical composition and use of a conjugate or a composition
AU2015358532A1 (en) 2014-12-03 2017-06-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201520557D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3458101A1 (en) 2016-05-20 2019-03-27 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3465221A1 (en) 2016-05-27 2019-04-10 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
WO2001000225A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISK BRYAN ET AL: "Identification of an Immunodominant Peptide of HER-2/neu Protooncogene Recognized by Ovarian Tumor-specific Cytotoxic T Lymphocyte Lines", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 181, no. 6, 1995, pages 2109 - 2117, XP009030958, ISSN: 0022-1007 *
KONO KOJI ET AL: "Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes", INTERNATIONAL JOURNAL OF CANCER, vol. 78, no. 2, 5 October 1998 (1998-10-05), pages 202 - 208, XP002280379, ISSN: 0020-7136 *
See also references of WO0141787A1 *

Also Published As

Publication number Publication date
WO2001041787A1 (en) 2001-06-14
CA2393738A1 (en) 2001-06-14
AU2087401A (en) 2001-06-18
JP2003530083A (en) 2003-10-14
EP1239866A1 (en) 2002-09-18
EP1568373A2 (en) 2005-08-31
EP1568373A3 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
AP1427A (en) method of delivering genes to antigen presenting cells of the skin
TWI315988B (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
SK123898A3 (en) Novel substituted cyclic amino acids as pharmaceutical agents
IL149164A (en) Methods and compositions utilizing quinazolinones
IL134754A (en) N-terminally pegylated consensus interferon compositions and methods
HU9901874A3 (en) Human antibodies binding human tnfalfa, pharmaceutical compositions containing thereof and use thereof
PL2335725T3 (en) High concentration antibody and protein formulations
IL147145D0 (en) ANTI-αvβ3 RECOMBINANT HUMAN ANTIBODIES AND NUCLEIC ACIDS ENCODING THE SAME
IL135314D0 (en) Novel amines as pharmaceutical agents
PL330456A1 (en) Cosmetic composition resitant to transferring
AU2001295490A1 (en) Antibodies to human IL-1beta
PL345539A1 (en) Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
IL127115D0 (en) Novel protein and method for preparing it
HK1012566A1 (en) Pharmaceutical formulations in form of thixotropic gel
SK9892001A3 (en) Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
MXPA02002107A (en) Compositions for stimulating cytokine secretion and inducing an immune response.
ZA9809013B (en) Taste masked formulations
IL144578D0 (en) Antibodies specific to kdr and uses thereof
EP1140175A4 (en) Antibodies to truncated vegf-d and uses thereof
IL121236D0 (en) Cycloalkano-pyridines their preparation and pharmaceutical compositions containing them
IL136551A (en) Preparation of peg-grf conjugates
IL121234A (en) Polysubstituted heterocyclic-fused pyridines their preparation and pharmaceutical compositions containing them
ZA9811501B (en) Method to enhance an immune response of nucleic acid vaccination.
HK1048435A1 (en) Combined vaccine compositions
EP1527100A4 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Legal Events

Date Code Title Description
AX Request for extension of the european patent to

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20020709

AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIN1 Inventor (correction)

Inventor name: CELIS, ESTEBAN

Inventor name: SIDNEY, JOHN

Inventor name: KEOGH, ELISSA

Inventor name: SETTE, ALESSANDRO

Inventor name: CHESNUT, ROBERT

Inventor name: FIKES, JOHN

Inventor name: SOUTHWOOD, SCOTT

A4 Despatch of supplementary search report

Effective date: 20041227

18D Deemed to be withdrawn

Effective date: 20050315

RIN1 Inventor (correction)

Inventor name: CHESNUT, ROBERT

Inventor name: SETTE, ALESSANDRO

Inventor name: CELIS, ESTEBAN

Inventor name: SIDNEY, JOHN

Inventor name: KEOGH, ELISSA

Inventor name: SOUTHWOOD, SCOTT

Inventor name: FIKES, JOHN